Understanding IGF-1 Signaling

What IGF-1 is

Insulin-like growth factor 1 (IGF-1) is a small protein hormone that gets its name from its close structural resemblance to insulin. It is one of the body's principal anabolic signals — the molecule that tells cells to grow, take up nutrients, synthesize protein, and resist programmed death. Much of what we attribute to growth hormone (GH) is, in fact, carried out by IGF-1 acting as GH's downstream messenger.

IGF-1 is produced mainly by the liver in response to GH, and it circulates to act on tissues throughout the body (endocrine action). It is also made locally within tissues such as muscle and bone, where it acts on nearby cells (paracrine) or the same cell (autocrine). This dual local-and-systemic production lets IGF-1 support both whole-body growth and targeted tissue repair.

The GH→IGF-1 axis

IGF-1 is the business end of the [growth hormone axis](/the-growth-hormone-axis-explained). The hypothalamus releases GHRH (and ghrelin acts as a secretagogue) to stimulate the pituitary, while somatostatin restrains it. The pituitary secretes GH in pulses; GH then travels to the liver and binds the GH receptor, triggering production and release of IGF-1. Circulating IGF-1, in turn, feeds back to suppress further GH release, closing the loop.

This is why IGF-1 is often measured as a stable readout of GH activity: GH itself is pulsatile and hard to capture in a single sample, whereas IGF-1 levels are relatively steady over the day. Research peptides that engage this axis — such as sermorelin, CJC-1295, and the growth-hormone secretagogue MK-677 — are studied specifically for their effects on GH and, downstream, IGF-1.

IGF-1R and PI3K/Akt/mTOR

IGF-1 exerts its effects through the IGF-1 receptor (IGF-1R), a receptor tyrosine kinase on the cell surface that is closely related to the insulin receptor. When IGF-1 binds, IGF-1R autophosphorylates and recruits adaptor proteins (such as IRS-1), launching two major intracellular pathways.

The first is the PI3K → Akt → [mTOR](/what-is-mtor) pathway, the dominant route for IGF-1's anabolic effects: it stimulates protein synthesis, glucose uptake, and cell survival, and it inhibits the pro-death and stress-response factors of the FOXO family. The second is the Ras/MAPK pathway, which drives cell proliferation and differentiation. Together these programs make IGF-1 a powerful growth and repair signal.

This signaling directly opposes catabolic brakes. Where myostatin restrains muscle growth through SMAD signaling, IGF-1's PI3K/Akt/mTOR arm pushes protein synthesis upward — so muscle size reflects the balance between them. Because IGF-1 activates mTOR, its signaling is also entangled with the AMPK–mTOR energy seesaw: abundant growth-factor signaling favors the build-and-grow state.

IGFBPs and the longevity trade-off

Free IGF-1 in the blood is minimal — the vast majority is bound to a family of six IGF binding proteins (IGFBPs), chiefly IGFBP-3. These proteins act as a reservoir and a regulator: they extend IGF-1's half-life from minutes to hours, control how much reaches receptors, and can either enhance or inhibit IGF-1 delivery depending on context. Any interpretation of IGF-1 activity has to account for this binding, not just total IGF-1 levels.

The IGF-1 axis illustrates a classic biological trade-off. Robust IGF-1 signaling supports growth, muscle and bone maintenance, and tissue repair — clearly beneficial during development and recovery. Yet across many model organisms, reduced IGF-1/insulin-like signaling is associated with extended lifespan, likely because dialing down growth signaling raises stress resistance, enhances autophagy, and activates protective FOXO programs. This is the same growth-versus-maintenance tension seen with mTOR and AMPK.

For related biology, see the growth hormone axis, the muscle-limiting factor myostatin, and research profiles for growth-focused compounds such as IGF-1 LR3 and MK-677. To explore more, browse the research library.